- Home
- PHAR vs STOK Comparison
PHAR vs STOK Comparison
Compare PHAR & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- STOK
- Stock Information
- Founded
- PHAR 1988
- STOK 2014
- Country
- PHAR Netherlands
- STOK United States
- Employees
- PHAR N/A
- STOK N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- PHAR Health Care
- STOK Health Care
- Exchange
- PHAR Nasdaq
- STOK Nasdaq
- Market Cap
- PHAR 627.5M
- STOK 721.4M
- IPO Year
- PHAR N/A
- STOK 2019
- Fundamental
- Price
- PHAR $8.18
- STOK $12.03
- Analyst Decision
- PHAR Strong Buy
- STOK Strong Buy
- Analyst Count
- PHAR 2
- STOK 7
- Target Price
- PHAR $33.50
- STOK $21.40
- AVG Volume (30 Days)
- PHAR 6.6K
- STOK 405.8K
- Earning Date
- PHAR 10-24-2024
- STOK 11-05-2024
- Dividend Yield
- PHAR N/A
- STOK N/A
- EPS Growth
- PHAR N/A
- STOK N/A
- EPS
- PHAR N/A
- STOK N/A
- Revenue
- PHAR $285,745,000.00
- STOK $16,742,999.00
- Revenue This Year
- PHAR $20.89
- STOK $91.67
- Revenue Next Year
- PHAR $11.15
- STOK $5.45
- P/E Ratio
- PHAR N/A
- STOK N/A
- Revenue Growth
- PHAR 30.64
- STOK 81.08
- 52 Week Low
- PHAR $6.65
- STOK $3.77
- 52 Week High
- PHAR $13.20
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- PHAR 47.63
- STOK 39.51
- Support Level
- PHAR $7.70
- STOK $13.39
- Resistance Level
- PHAR $8.28
- STOK $14.72
- Average True Range (ATR)
- PHAR 0.41
- STOK 0.68
- MACD
- PHAR -0.07
- STOK 0.03
- Stochastic Oscillator
- PHAR 44.27
- STOK 7.24
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.